Table 1—

Baseline characteristics of the patients under study

Iloprost groupBosentan groupp-value
Subjects n1318
Female/male n8/59/90.717
NYHA II1 (8)0 (0)0.419
NYHA III12 (92)16 (89)1.0
NYHA IV0 (0)2 (11)0.497
Age yrs44±848±110.144
6-min walk distance m343±116358±1010.435
RAP mmHg6±59±60.204
―Ppa mmHg51±752±70.832
CO L·min−14.9±1.64.6±1.30.735
CI L·min−1·m−22.6±0.62.4±0.60.352
PVR dyn.s.cm−5812±337866±4220.866
Sv,O2 %65±962±80.204
FVC % pred94±1592±170.882
FEV1 % VC75±673±100.250
DL,CO % pred68±1660±170.209
Pa,O2 mmHg79±1366±90.002
Pa,CO2 mmHg31±332±40.767
Aetiology of cirrhosis
 Alcoholic6 (46)11 (61)0.481
 Viral hepatitis2 (15)3 (17)1.0
 Autoimmune4 (31)2 (11)0.208
 Other1 (8)#2 (11)1.0
Child A10 (77)18 (100)0.064
Child B3 (23)0 (0)0.064
MELD score12±310±30.09
  • Data are presented as n (%) or mean±sd, unless otherwise indicated. NYHA: New York Heart Association; RAP: right atrial pressure; ―Ppa: mean pulmonary artery pressure; CO: cardiac output; CI: cardiac index; PVR: pulmonary vascular resistance; Sv,O2: mixed venous oxygen saturation; FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in one second; VC: vital capacity; DL,CO: diffusion capacity of the lungs for carbon monoxide; Pa,O2: arterial oxygen tension; Pa,CO2: arterial carbon dioxide tension; MELD: Model End-stage Liver Disease. #: bile duct atresia; : one cryptogenic and one idiopathic portal vein thrombosis. The MELD score is a disease severity score in patients with cirrhosis (see text for details). 1 mmHg = 0.133 kPa.